North American Medical Adhesives, Skin Contact Tapes and Sealants: Supply Base and Application Map

There are two adhesive businesses inside medical devices and they are not variations on each other. They share a supplier base, a set of trade shows, and a regulatory vocabulary, and almost nothing else.

The first is device assembly adhesive. A catheter tip bonded to a shaft, a cannula fixed into a needle hub, a luer bonded to a line, a hollow fiber bundle potted into a dialyzer header, a housing seam closed on a bedside monitor. These are ordinary industrial bonding problems carrying a medical burden: the cured adhesive has to pass ISO 10993 biocompatibility testing for the contact category it falls into, the supplier has to sign a change control agreement, and the process has to be validated. That burden is real and it is finite. Once it is carried, several companies can serve any given bond, and they compete. Margins look like industrial adhesive margins with a compliance premium on top.

The second is skin contact adhesive, and it is a different industry wearing the same word. The material has to adhere to human skin for hours or days, through perspiration, showering, clothing friction, and motion, across a patient population whose skin ranges from a healthy adolescent to a ninety year old on anticoagulants and topical steroids, and then release without injury. There is no bench test that fully predicts it. The specification is written in wear time, peel from skin rather than from steel, moisture vapour transmission rate, and irritation and sensitisation results from ISO 10993-10, and the confirming evidence is clinical. Very few companies in North America can formulate, coat, and defend such a material, and the ones that can are not competing on price.

The commercial asymmetry follows directly. Device assembly adhesive is a competitive business a capable formulator can enter within a year through the contract manufacturers. Skin contact adhesive is a multi-year investment in formulation capability, biocompatibility data, coating assets, and a reference list, and it pays several times better.

The growth is entirely on the skin side. Continuous glucose monitors, patch pumps, on-body injectors for high volume biologics, and remote cardiac monitoring patches have created demand for adhesives that hold a device with real mass on an arm or an abdomen for a week or two, in normal life, on a patient who did not choose to have it there. Ten years ago a fourteen-day wear requirement was a research question. Today it is a purchase order, repeating, at volumes that make it the fastest growing adhesive category in any industry in this catalog.

Two more facts belong up front. Adhesive is a small fraction of the cost of a device and a large fraction of the risk, because an adhesive failure on a skin contact device is a patient injury and an adhesive change can require a new regulatory submission. And nothing here moves fast. A qualified adhesive on a shipping device is written into a device master record, and displacing it means the customer has to want to revalidate. That makes this market slow to win and very slow to lose.

Four tiers, and the split inside Tier 1 and inside Tier 2 matters more than the tier boundaries.

The device OEM sits at the top and specifies almost everything. Sixteen OEM organisations hold position rows in this industry, from Medtronic, Abbott, and Becton Dickinson through Boston Scientific, Baxter, and Stryker to ResMed, Hologic, and ICU Medical. Unlike the brand owners in consumer electronics, most of them still manufacture, and many buy adhesive directly. What they always own is the specification, the regulatory filing, and the change control process that sits on top of the specification. A material that is in a device master record is there because an OEM engineer put it there and a quality organisation accepted it.

Tier 1 splits into assemblers and converters. The contract manufacturers, Jabil Healthcare, Integer Holdings, Phillips-Medisize, Nordson MEDICAL, and Tekni-Plex, build devices and are the buyers of record for assembly adhesive. They hold the purchase order, run the dispensing and light-cure equipment, and own the process validation, which is a deeper commitment than a purchase order: a validated dispense-and-cure process is expensive to re-run, and that is what makes an incumbent adhesive hard to move.

The converters are the other half of Tier 1 and on the skin contact side they are much more than a channel. A wound dressing, an ostomy wafer, and a sensor patch reach an OEM as a finished laminate: coated, laminated, die-cut, pouched, and often sterilised. The company doing that work, Scapa Healthcare, Web Industries, Marian, JBC Technologies, or Boyd, is performing most of the manufacturing of the finished product. Several of them also coat their own adhesive, which puts them in Tier 2 at the same time.

Tier 2 is the formulators, and it splits by discipline rather than by size. On the skin contact side, 3M Medical Materials and Technologies is the category leader and the reference against which everything else is measured, with Avery Dennison Medical, Adhesives Research, Scapa, and Nitto as the other credible coaters, and Dow and Elkem supplying the soft silicone gel chemistry that has been taking share from acrylic for a decade. On the device assembly side the names change: Henkel through Loctite, Dymax in light cure, Master Bond in small-lot specification work, and H.B. Fuller across disposables construction and cyanoacrylate. Only 3M, Henkel, and Dow are genuinely present in both halves.

Tier 3 is silicone and monomer chemistry, and it is short. Dow, Elkem, Momentive, and Shin-Etsu supply the siloxane polymers, gums, and gel base systems behind every silicone adhesive above them, and Arkema supplies the acrylic monomers behind the acrylate ones. Four silicone suppliers sit underneath the entire soft skin adhesive category, which is a concentration worth understanding before building a product line on it.

Distribution is thin and it is not a catalog. Ellsworth Adhesives and Krayden carry the reactive assembly chemistry with the dispensing and cure equipment and the application engineering attached, which is how a contract manufacturer buys and supports a process rather than a drum. Foster Corporation is the specialty channel for small medical programs. Skin contact material largely does not go through distribution at all: it is sold as a coated construction, direct, against a customer specification, which is itself a statement about how different the two halves of this lens are.

The sixteen device OEMs in this industry buy adhesive in four recognisably different ways, and the difference tracks what the adhesive touches rather than how large the company is.

The wearables and diabetes OEMs are the skin contact accounts that matter. Abbott, through FreeStyle Libre, and Medtronic, through its diabetes business, buy skin contact adhesive at a volume and a wear time that did not exist as a market fifteen years ago. So does every patch pump and on-body injector program in the industry. These are the hardest technical conversations in this lens and the most valuable: the adhesive is a named risk in the design history file, the wear time is a marketing claim, and removal trauma is a complaint category the OEM tracks. A supplier that can hold fourteen days and come off gently is not quoting against a price list.

The catheter and interventional OEMs are the assembly adhesive accounts. Boston Scientific, Teleflex, Terumo, Edwards, and Integra build products that are, structurally, a series of bonded joints. Light-cure acrylate dominates and the purchase frequently sits at a contract manufacturer rather than at the OEM, because so much catheter work is outsourced. The specification still sits with the OEM, and the pull test that the bond has to pass is written into a released drawing.

The disposables and hospital products OEMs buy both, in enormous quantity, on cost. Becton Dickinson, Baxter, B. Braun, ICU Medical, and Cardinal Health consume needle hub bonds, luer bonds, potting compound, drape and dressing adhesive, pouch and tray sealing, and label stock across product lines that run for decades at very high volume. These are the most price-disciplined accounts in the roster, and also the stickiest: at these volumes a validated material change is a capital-scale project and nobody undertakes one casually.

The capital equipment and reusable device OEMs are a smaller, different business. Stryker, Hologic, and ResMed build enclosures, optical assemblies, and patient interfaces that have to survive repeated disinfection or reprocessing. Volumes are modest, the engineering content per part is high, and the failure mode is chemistry rather than load: a housing bond that is fine mechanically and crazes after six months of quaternary ammonium wipe-down is the recurring problem in this group.

One practical note across all sixteen. Medical device OEMs do not casually re-specify. An adhesive in a shipping device is in a device master record, and on a skin contact device an adhesive change can require a new 510(k) submission. That is the wall in front of every displacement attempt in this report, and it is also the reason an incumbent position here is worth more than an equivalent position in almost any other industry in this catalog. Win at design, or wait for the next platform.